By Iain Wilkie
18 August 2022, 4:00 PM
Pro Medicus (ASX:PME) recorded another year of strong growth across all metrics with the key highlight being further EBIT margin expansion to 67% well above expectations, highlighting the operating leverage of the business.
Read more...
By Adrian Prendergast
18 August 2022, 9:00 AM
Santos' (ASX:STO) strong 1H22 result close to estimates, while interim dividend trailed.
Read more...
By Dr Derek Jellinek
18 August 2022, 8:30 AM
CSL Ltd (ASX:CSL) FY22 results were slightly softer than expected, albeit in line with management’s assumptions, with net profit falling 6% in cc on 3% revenue growth.
Read more...
By Belinda Moore
18 August 2022, 8:00 AM
Corporate Travel Management's (ASX:CTD) FY22 result beat its guidance, our forecast and consensus following a particularly strong 4Q22 recovery.
Read more...
By Alex Lu
18 August 2022, 7:30 AM
Brambles' (ASX:BXB) FY22 result was above expectations and updated guidance given in April.
Read more...
By Alexander Mees
18 August 2022, 7:00 AM
Super Retail Group (ASX:SUL) surprised the market by reporting much more resilient earnings in FY22 than had been forecast.
Read more...
By Andrew Tang
18 August 2022, 6:30 AM
Today, Thursday the 18th of August, we are happy to buy CSL Limited (ASX:CSL), Corporate Travel (ASX:CTD), Santos (ASX:STO) and Super Retail Group (ASX:SUL).
Read more...
By Tom Sartor
17 August 2022, 10:00 AM
Equity Strategist Tom Sartor takes us through the key results and themes of Reporting Season (August 2022) thus far, with over 25% of the top 50 ASX companies having reported results.
Read more...
By Richard Coles
17 August 2022, 9:00 AM
Challenger Financial Svcs' (ASX:CGF) result overall was a bit weak in our view, with a reasonable current year performance offset by the negatives of a softer FY23 outlook than expected, and a decision to conduct a strategic review of the bank.
Read more...
By Steven Sassine
17 August 2022, 8:20 AM
SEEK's FY22 topline result (~A$1.12bn, +47% on pcp) came in ~2% above the upper end of management's guidance. View our analysis.
Read more...